Replies to post #61237 on Anavex Life Sciences Corp (AVXL)

[BCCHoosier]

Agree. This is going to take much longer than many are willing to wait. I am patient and willing to ride this out to 3019 or 2020. Going to need a partner soon. Slow and steady...one step at a time.

[hfb46]

My comment is based upon the premise that we continue to get good results as data continues to be released, and that we do indeed attract the attention of some BP companies. I would be very surprised if management would agree to a buy out. The compounds in our pipeline have too much potential for too many CNS conditions, to "sell the store" so early in the game. Of course a deal COULD be struck where AVXL retains the rights to a certain percentage of potential profits going forward, assuming a compound is successful in the market place. But those types of deals can be cumbersome and many companies shy away from such. Also, a deal could be structured whereby the rights to one compound is sold, and thus allowing for the sale proceeds to fund studies in one of our other compounds. But I would think that at this time, Missling is focused on obtaining a "partner", not a "buyer". JMO

[XenaLives]

My response to your points -

1. why the media blitz from Dr mac? Typically lead PI are not so vocal - such publicity brings bias and could seen as impacting results.

2. Partnership - will be needed for P3 - it is long and expensive journey - Dr M probably does not have right resources to handle such large trial and also sustain for long time.

3. If 26 weeks results are good - hopefully we get decent BO offer from BP based on potential and as individual investors we make good money and drug goes into right hand to go toward and approval.

Here is P3 study of Biogen for their most promising ALZ drug - 1350 patients - starting in 2015 - recruitment till 2020 - results 2022
There are 2 of them

Can AVXL handle such large trials

1) I think he is drumming up interest to speed trial recruitment. He does not appear to be concerned with bias and it's probably for the same reason that the placebo effect isn't seriously being considered to explain the dramatic life changing nature of the drug that has been observed so far.

2) Partnership(s) are probably already on the table.

3) Accepting a buyout at this time would be unfair to shareholders. We have enough insider control of the stock to ensure that such unfairness does not occur. I believe a partnership is the primary goal.

4) The Biogen study is large and recruitment is slow because they have to deal with toxic side effects and carefully choose very early diagnosis because the aim of the study is to slow the onset of the disease and this is harder to prove than disease reversal. Apples and oranges...